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Latar belakang kajian: Reagen potensi peningkatan seperti LISS dan PEG telah 
digunakan secara meluas dalam ujian saringan antibodi untuk mempercepatkan reaksi 
aglutinasi antibodi sel darah merah (SDM). Nanopartikel emas dengan ciri-cirinya yang 
stabil secara kimia dan mudah diubahsuai, telah terbukti dalam memudahkan reaksi ini. 
Oleh itu, kajian ini bertujuan untuk menghasilkan satu larutan alternatif dengan 
menggunakan gabungan PEG dengan nanopartikel emas (PEG AuNP). 
 
Rekabentuk kajian: Sintesis satu langkah melalui konjugasi telah digunakan untuk 
pembentukan PEG AuNP dengan kehadiran NaOH mengakibatkan pembentukan yang 
cepat. Larutan yang baru dihasilkan ini telah dicirikan dengan menggunakan 
spektrofotometer UV-VIS pada suhu bilik di seluruh gelombang spektrum 200nm hingga 
700nm. Ujian saringan antibodi bagi tiga sampel telah dilakukan dengan membandingkan 
reagen potensi peningkatan yang berbeza (LISS, PEG, Gold, dan PEG AuNP), dan antara 
kepekatan PEG AuNP yang berbeza pada fasa antiglobulin untuk reaksi aglutinasi 
antibodi SDM.  
 
Keputusan kajian: PEG AuNP telah berjaya disintesis berikutan perubahan warna dari 
telus kepada ungu dan menunjukkan pada penyerapan maksimum 565nm. Larutan PEG 
AuNP menunjukkan skor reaksi yang sama dibandingkan dengan LISS dan PEG dalam 
ujian saringan antibodi. Tidak terdapat perbezaan yang signifikan dalam skor aglutinasi 




Kesimpulan: PEG AuNP yang baru dihasilkan ini mampu membantu dalam reaksi 
aglutinasi antibodi SDM dan dengan itu boleh menjadi reagen potensi peningkatan 
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Background:  Enhancing potentiators such as Low Ionic Strength Solution (LISS) and 
Polyethylene Glycol (PEG) have been widely used to facilitate red blood cell (RBC) 
antibody agglutination reaction. Gold nanoparticles with its inert and tunable property, 
have been proven in fastening this reaction. Hence, this study aimed to develop an 
alternative enhancing potentiator for RBC antibody agglutination by using the 
combination of PEG and gold nanoparticle (PEG AuNP). 
 
Methods: One step synthesis through conjugation has been used for the development of 
PEG AuNP in the presence of sodium hydroxide (NaOH) resulted in the fast formation 
of PEG-coated gold nanoparticle. Characterisation of the newly developed solution was 
performed using UV-VIS spectrophotometer at room temperature across the spectral 
wavelength of 200nm until 700nm. Antibody screening test for three samples were 
performed comparing between enhancing potentiators (LISS, PEG, Gold, and PEG 
AuNP), and between different PEG AuNP concentrations at antiglobulin phase for RBC 
antibody agglutination reaction.  
 
Results: PEG AuNP was successfully synthesised as the colour changes from transparent 
to violet and showed maximum absorbance at 565nm. The PEG AuNP solution showed 
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similar reaction score as compared to LISS and PEG alone in antibody screening test. 
There was no significant difference in agglutination score between various concentration 
of PEG AuNP (p = 0.4).  
 
Conclusion: The newly developed PEG AuNP is capable to potentiate RBC antibody 









1.0 Background of study 
 
Blood transfusion is remarkably safe and plays a vital role in routine clinical management 
(Seitz & Heiden, 2010). The requirement of blood transfusion varies between the different 
blood products or components used. For instances, red blood cells (RBCs) transfusion is 
required in bloos loss, haemorhage, and it is also used to increase tissue perfusion and 
oxygenation such as in patient with symptomatic anemia, acute sickle cell diorder, or 
massive blood loss. Fresh frozen plasma is used to reverse the anticoagulant effect and 
coagulation factor deficiencies. While platelet is indicated in patient with underlying 
thrombocytopenia and platelet function disorders; and cryoprecipitate is used to treat for 
fibrinogen deficiency (Sharma et al., 2011). 
 
Pre-transfusion testing is an essential laboratory testing that is required prior to any 
transfusion. This test is performed by testing both patient’s sample and the intended blood 
components to check for the compatibility between the patient and the blood product 
intended to be transfused especially for RBC products (Lane, 2017).  
 
In pre-transfusion testing, ABO and Rh(D) grouping will be performed by forward and 
reverse grouping. In addition, patients’ plasma will also be tested for antibody screening 
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to detect the non-ABO clinically significant antibodies that may cause severe transfusion 
reactions. This is because, beside ABO grouping which serves as the most important 
blood group contributed to acute haemolytic transfusion reaction, there are also presence 
of non-ABO antibodies that are clinical significant (Makroo et al., 2014). These 
alloantibodies may develop following sensitisation through pregnancy or previous blood 
transfusion and can cause either acute or delayed transfusion reaction (Al-Joudi et al., 
2011). Thus, antibody screening is an important steps in pre-transfusion testing that acts 
as the first guard to ensure a safe transfusion.  
 
Crossmatching between the patient’s blood and the donor’s RBC will be performed as 
the last guard in pre-transfusion testing to ensure ABO compatibility between recipients 
and the blood product that intended for transfusion; and to detect the clinically significant 
antibodies that may not detected from the antibody screening test. Any agglutination 
reaction indicated incompatibility between the transfusion recipients and the blood 





1.1 Problem statement 
 
For antibody screening test, it took about 30 to 60 minutes to detect any clinically 
significant of unexpected antibodies (Aronson et al., 2011). This is a critical part to be 
concerned as for some serious cases such as acute massive bleeding, time is an important 
factor to reduce further mortality and morbidity in managing patient (Choktaweesak et 
al., 2016). Moreover, if there are presence of unexpected antibodies, further test which is 
antibody identification will be performed. Antibody identification may take several hour 
to days and thus may jeopardise the patients’ life who in need of an urgent blood 
transfusion. 
 
In addition, there are still some clinically significant antibody that will be missed out 
during the antibody screening such as those antibodies against low incidence antigens and 
those that who show dosage effect (Milkin et al., 2013). If the antibody is not detected 
during pre-transfusion testing, it will have a detrimental effect to patient such as adverse 
transfusion reaction (Resnick et al., 2008).  
 
Hence, in order to address these problems, enhancing reagents or potentiators such as 
Low Ionic Strength Solution (LISS), albumin, polyethylene glycol (PEG) have been used 
extensively in blood bank service to facilitate and expedite the antibody screening test. 
However, these enhancing reagents are costly to be used in most of the blood bank 




1.2 Research justification 
 
Enhancing reagent or potentiator such as LISS and PEG are widely used in blood bank 
service due to capability to shorten the antibody screening test duration from 30 minutes 
to 15 minutes. Currently, gold nanotechnology is a popular trend that has been extensively 
being tested in medical sector due to its comprehensive function (Longo et al., 2011; 
Ulbrich et al., 2011) for example, it has been reported from Wiwanitkit and his colleagues 
(2007) that gold can be used to enhance antibody-antigen agglutination reaction and can 
even facilitate in enhancing protein reaction and detecting weak subgroup system. 
Therefore, in our study, we aimed to develop an alternative solution using PEGylated 
gold nanoparticle (PEG AuNP) that may facilitate and expedite the antibody-antigen 




1.3 Research objectives 
 
General: 
To develop a solution for enhancement of RBC antibody agglutination reaction using 
PEG and gold nanoparticle (PEG AuNP). 
 
Specific: 
I. To synthesis a new agglutination enhancing solution using PEG and gold 
nanoparticle. 
II. To characterise the newly synthesised PEG AuNP solution. 












2.0 Antibody screening 
 
There are variety of proteins and carbohydrates based antigens on the membrane of the 
RBC. Approximately, there are over 600 RBC antigens which are divided into 36 blood 
group systems nowadays (Rath et al., 2014). The existence of the antigens will determine 
the identity of one’s blood group system such as ABO blood group and Rh(D) blood 
group.  
 
During antibody screening procedure, patients’ serum is used to detect any unexpected 
antibodies present within it other than naturally occurring anti-A and anti-B. Patient’s 
serum is tested against known commercial O RBC embedded with variety of clinically 
significant antigens onto it. Normally, two panel cells or three panel cells will be used in 
antibody screening for detection of the unexpected antibodies (Fung et al., 2014). 
 
Antibody screening is performed at three phases namely immediate spin (IS), incubation 
at 37 °C, and at antihuman globulin (AHG) phase. Immediate spin phase is performed at 
room temperature to detect IgM or “cold” antibodies, and it is done without the need of 
any incubation (Fung et al., 2014). After IS phase, enhancement reagent will be added 
and the test will be incubated at 37°C in order to create an enhanced environment for 
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antigen-antibody reaction to occur. After incubation phase, any positive reaction in term 
of agglutination in AHG phase will be considered as clinical significant antibodies 
presence in the patient’s blood. Profoundly, AHG phase is to provide enhancement 
environment for antigen-antibody reaction for second stage of RBC antibody 
agglutination reaction (Pathak et al., 2011). 
 
2.1 Clinically significant antibodies 
 
Nowadays, all the blood transfusion services’ centre confront the problem that 
procrastinating of blood for urgent transfusions (Chowdhry et al., 2014). This is mostly 
due to the antibody screening test (AST) that gained a positive result. Once positive result 
in AST yielded, antibody identification must be performed prior to any transfusion 
activity (Green et al., 2015). 
 
The RBC antibodies can be divided into either clinically significant or non-clinically 
significant antibodies. Clinically significant antibody is normally reactive at AHG phase 
while antibody that react below 37ºC is commonly not clinically significant and may not 
elicit any clinical symptoms (Pathak et al., 2011). 
 
These clinically significant RBC antibodies have known to cause haemolytic transfusion 
reaction (HTR) as well as haemolytic disease of the foetus and new-borns (HDFN) 
(Chowdhry et al., 2014). The example of common non-ABO clinically significant blood 
group systems include Rh, Kell, Kidd, Duffy, MNS, and P (Armstrong et al., 2008). A 
summarised table that depicting the clinically significant antibodies to the blood group 
antigen of majority are tabulated below (Table 2.1) (Christopher et al., 2004): 
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Table 2.1 Clinically significant antibodies with respect to its blood group systems. 
Common Clinically significant Clinically Significant if Reactive at 
37ºC 
A and B A1 
Diego H 
Duffy Lea 
H in Oh Lutheran 





S, s, U  
Vel  
 
2.2 Antigen-antibody reaction 
 
The AST involves the detection of unexpected antibody agglutination between the RBC 
antigen and antibody interactions (Milkin et al., 2013). The RBC antibody agglutination 
process can be divided into two stages namely first stage of non-visible sensitisation and 
second stage of visible agglutination. First stage of non-visible sensitisation involves the 
binding of the RBC antibodies binding to its antigens on the RBC’ membrane. The second 
stage of visible agglutination, is a stage whereby the antibody sensitising RBC will collide 






Figure 2.1 Representation of the RBC antibody agglutination reaction. Blood group 
antigens and antibodies formed a lattice bridge of RBC and caused agglutination. 
 
2.3 Factor affecting antigen-antibody agglutination reaction 
 
There are many factors that can influence the reaction between antigen and antibody in 
laboratory testing and can be categorised as factors that affect the sensitisation or 
agglutination stage.  
 
2.3.1 Factors affecting sensitisation stage (Stage 1) 
During non-visible sensitisation, serum-to-cell ratio plays an important role to increase 
chances of the antigen-antibody collision in order to achieve higher probability of 
sensitisation event to occur. Serum contains antibody, and thus by increasing the serum 
amount in the test, it may increase the binding of those antibodies to the RBC antigen 




In addition, different antibody will react effectively at different temperature (Kathy and 
Paula, 2009). For example, cold type RBC antibodies such as anti-Lea, anti-Leb, anti-I, 
anti-P1, anti-M and anti-N are stable and reactive at lower temperatures, mainly at or 
below ambient room temperature about 20-24ºC, whereas other clinically significant 
antibodies are IgG antibodies in nature such as anti-D, anti-K, anti-Jka, anti-Jkb, anti-Fya, 
anti-Fyb, anti-S, and anti-s are react best at temperature of 37ºC (Kathy and Paula, 2009). 
Thus, by incubating the testing sample in respective temperature, it can further enhance 
the first stage of agglutination reaction (Encarnação et al., 2017). 
 
Furthermore, RBC antibody reacts most effectively with the physiological condition of 
pH nearly to neutral, seven. Out of this pH range, there will be inhibition of the antigen-
antibody activity (Kathy and Paula, 2009). This is due to the reason that, extreme pH will 
cause alteration of the antibody conformation and aftermath incompatible to the antigen 
determinants (Reverberi and Reverberi, 2007). According to Martin and his colleagues 
(2014), phosphate buffered saline (PBS) is recommended to be used in RBC washing as 
compared to normal saline solution (NSS) because NSS pH tend to have more fluctuation 
as the storage time increases. Furthermore, PBS pH can be maintained at longer period 
of time and more stable without any significant fluctuation (Martin et al., 2014).  
 
Moreover, ionic strength is another contributing factor that may affect the RBC antigen-
antibody agglutination reaction in vitro. Under isotonic circumstances in saline solution, 
sodium ions and chloride ions tend to bind to the opposite charged groups on both antigen 
and antibody molecules, and decreasing their affinity to attract each other to cause 
sensitisation (Kathy and Paula, 2009). Thus, the reaction of RBC antigen-antibody 
reaction is hindered. According to Reverberi and her colleague (2007), there will be 
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increase in the antibody titre by lowering ionic strength in the in vitro environment. This 
is due to the lessen hindering effect and increased in the uptake of antibody to 
corresponding antigens (Kathy and Paula, 2009).  
 
2.3.2 Factor affecting lattice formation stage (Stage 2) 
 
Once the RBC is sensitised with antibody, random collision is needed between the 
sensitised RBC to form a crosslink relationship in visible agglutination stage or lattice 
formation stage in vitro. 
 
In nature, RBC membrane has a net of negatively charged ions due to the presence of 
sialic acid onto it in physiological saline solution environment (Figure 2.2) (Fernandes et 
al., 2011). This net of negatively charge will get attracted by positively charged ions in 
the solvent system. The equilibrium of the positively charge masked RBC will repulse 
each other in the physiological saline environment and this will keep RBC from being in 
the vicinity of one another (Brecher, 2005). This phenomenon is called zeta potential, an 
electrostatic potential between the RBC in the dispersed system (Fernandes et al., 2011). 
 
Figure 2.2 Zeta potential effect on the second stage of agglutination. Figure adapted from 
Fernandes his colleagues (2011). 
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Therefore, it is important to reduce the zeta potential so that there will be higher 
probability of positively charged antibodies to overcome the repulsion force and get 
closer to the negatively charged sialylated RBC membrane and eventually promoting the 
visible agglutination reaction (Caruccio and Wise, 2013). 
 
Different antibodies have different morphologies in their nature and tend to have different 
aptitudes with respect to agglutination. Size of the immunoglobulin plays role in different 
binding ability (Kathy and Paula, 2009). In term of agglutination, IgM antibodies tend to 
have more binding efficient ability than IgG (Fernandes et al., 2011). This is due to the 
reason that IgM is pentameric large molecule with 970 kDa and by having five Y shaped 
units with ten antigen binding sites which can facilitate the agglutination between cells. 
Whereas IgG is comparatively smaller in size with 150 kDa and having merely one Y 
shaped units equipped with two antigen binding sites causing them difficult to span the 
distance between neighbouring cells produced by the zeta potential (Carl and David, 
2014). Thus, the binding efficiency of IgG to its antigen is comparatively lower for visible 
agglutination reaction (Kathy and Paula, 2009). Hence, antihuman globulin (AHG), a 
polyclonal anti-IgG reagent is used in all laboratory and blood bank service to address the 
hurdle of IgG visible agglutination by forming a stable lattice bridge and caused 
agglutination when anti-IgG attaches to the IgG sensitised RBC (Pathak et al., 2011). 
 
Ratio between antibody and antigen should be equivalent for agglutination reaction to 
occur. Thus, the amount of antibody and antigen should be in optimal condition in the 
agglutination zone of equivalence. There are three zones in immunoagglutination reaction 
namely Prozone, Zone of Equivalence, and Postzone. Prozone is defined when the serum 
antibody concentration is higher compared to the concentration of antigen presence 
(Tankeshwar, 2010). During this zone, most probably antibodies will only bind to RBC 
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univalently instead of multivalently and cause no crosslink between RBC and thus giving 
a false-negative result. While postzone is the opposite of prozone, and resulted in the 
excessive of antigen over the antibody presented in the serum which also likely to cause 
a false-negative result (Figure 2.3) (Tankeshwar, 2010). Therefore, range of two to five 
percent of red cell suspension in saline in blood bank setting result in the optimal 
concentration for antigen concentrations to let the reaction fall into the equivalent zone 
to cause agglutination reaction (Kathy and Paula, 2009). 
 
 
Figure 2.3 Effect of agglutination observed in the zone of equivalence. Figure adapted 
from Tankeshwar (2010). 
 
Last but not least, centrifugation plays a role for the visible effectiveness of antigen-
antibody agglutination reaction. Appropriate time and speed of centrifugation aid in the 
formation of lattice bridge within close range of RBC in the test environment (Kathy and 
Paula, 2009).  
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2.4 Antibody potentiators or enhancement media 
 
The RBC antibody agglutination reaction can be enhanced in the presence of antibody 
potentiators. These potentiators can be used to further expedite in vitro agglutination 
(Kathy and Paula, 2009). There are three types of common potentiators that are normally 
used in blood bank such as low-ionic strength solution (LISS), polyethylene glycol (PEG), 
and proteolytic enzymes. 
 
2.4.1 Low-ionic strength solution (LISS) 
 
LISS is the most commonly used as an antibody potentiator for agglutination reaction 
detection. LISS comprises of 20% lower concentration of sodium chloride as compared 
to ordinal isotonic saline solution (Fernandes et al., 2011). LISS offers several advantages 
in term of time reducing for incubation from 30 to 15 minutes, improvement in 
agglutination reaction, and decrease in zeta potential between RBC, and enhancing the 
antibody uptake by the antigen (Choktaweesak et al., 2016). In physiologic saline 
environment, sodium ions and chloride ions tend to bind to the opposite charged groups 
on both antigen and antibody molecules, and thus decreasing their affinity to attract each 
other in the antigen-antibody complex formation (Kathy and Paula, 2009). Thus, LISS 
caters a lower number of sodium and chloride ions in the solution which subsequently 
reduces the ionic cloud formation encircled the RBC and promotes stronger association 
between the antigen-antibody complexes, and ultimately reduced the incubation time. 
Profoundly, ionic strength that is decreased by LISS can reduce the thickness of the 
cations net charge or ionic layers, result in decreasing of zeta potential and enhance the 
antigen-antibody agglutination reaction (Fernandes et al., 2011). However, according to 
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Garg and his colleagues (2017), LISS reported to have less efficiency towards certain 
antibody detection such as Kell’s antibodies (Anti-K). 
 
2.4.2 Polyethylene Glycol (PEG) 
 
PEG is another enhancement media that can be used in blood bank test.  PEG is a type of 
polymer that has a linear chain and is water soluble in nature with molecular formula of 
HO-(CH2CH2O)n - CH2CH2OH. The PEG’s OH group can bind with other molecules or 
surfaces covalently in order to facilitate the stabilisation of the compound (Fernandes et 
al., 2011). Therefore, PEG will eliminate the water from the RBC membrane, reduce the 
distance between RBC, and concentrate the antibodies to allow a greater odd of random 
collision between the antigen and antibody in the test environment (Fernandes et al., 
2011). In addition, Wang and his colleagues (2004) showed PEG able to facilitate antigen-
antibody complexes, and aids in signals’ amplification which enhances the sensitivity of 
the system. Besides that, PEG is better in detecting anti-K, anti-E, anti-c, and anti Jka as 
compared to LISS (Reverberi and Reverberi, 2007; Okutsu et al., 2011). According to 
Nance and Garratty (1997), the optimal concentration used was reported to be at 20% w/v 
with the PEG molecular weight (MV) of 4000. However, as a precautionary step while 
using as potentiator, centrifugation after incubation phase is unnecessary as centrifugation 
can cause aggregates formation of PEG and make it difficult to resuspend after washing 
procedures, and subsequently can give false positive reaction. Thus, if PEG is used, AHG 
phase is performed following incubation phase to eliminate the possibility of getting a 





2.4.3 Proteolytic enzymes 
 
There are many proteolytic enzymes normally used in immunohematology laboratory or 
blood bank in term of agglutination reactions such as papain, ficin, bromelin, trypsin, 
dispase, chymotrypsin, and neuraminidase which are commonly available in the market. 
Within a variety of proteolytic enzymes, bromelin and papain are more commonly used 
(Armstrong et al., 2008). These proteolytic enzymes alter the sialylated RBC’ membrane 
by eliminating the anion charges on the surface and therefore reducing the zeta potential 
and subsequently result in agglutination (Figure 2.4) (Fernandes et al., 2011). The 
reaction of enzymes with respect to RBC antigens are showed in with respect to its target 
antigen as summarised in the Table 2.2 (Armstrong et al., 2008): 
 
Table 2.2 Enzyme addition with respect to enhancement or denaturation of antigens 
(modified from Armstrong et al., 2008). 
Antigen enhanced by enzyme addtion Antigen showed no changes/ denatured 













Figure 2.4 Action of enzyme on sensitised red blood cells. Figure adapted from 
Armstrong and his team (2008). 
 
2.5  Nanotechnology 
 
Recently, there are many ongoing intensive researches on the field of nanotechnology 
from a wide range of application in term of physical, chemical, biological, and 
engineering sciences. Nanotechnology results in a promising and revolutionary in the 
field of medical application by interconnecting with biological molecules. 
Nanotechnology or sometime called as nanoscience which interchangeable denoted that 
the particle study that can be grouped as a certain number nanometers in size or having a 
nanoscale of less than 100nm in measurement (Tiwari and Tiwari, 2014). Besides, many 
proteins are in approximately 10 nanometers in size which can be specifically designed 
according to its nanoscale incorporated into the system of biology (Eustis and El-Sayed, 
2006). An exponentially increased in nanoparticle publications with the nanomaterials of 
gold and silver since 1990 (Eustis and El-Sayed, 2006). The development of nanoparticles 
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has attracted many researchers to enhance and improvise the synthesis of nanoparticles 
for biological and medicine application (Eustis and El-Sayed, 2006). 
 
2.5.1 Gold Nanoparticles 
 
Gold nanoparticles (AuNP) have been broadly used in wide range of biomedical fields 
owing to their high biocompatibility, optical electronic properties, good conductivity, 
having large surface area, and not hassle to be synthesised (Khan et al., 2014). 
Importantly, gold nanoparticles has low toxicity and has high chemically inertness 
properties which are safer to be used in in vitro testing without affecting the chemical 
equilibrium in the system (Giljohann et al., 2010). Besides that, gold nanoparticles have 
tunable properties chemically and physically which can be interacted with different 
biological macromolecules and organic molecules for instance antibodies and 
oligonucleotides (Khan et al., 2014). According to Jazayeri and his colleagues (2016), 
AuNPs with high electron densities have increase the cellular uptake while interacting 
with the cell membranes. In addition, gold nanoparticles can form a strong linkage exist 
between nanoparticle-protein interactions, immunogenecity and cytotoxicity while 
interact with human serum (Ajdari et al., 2017). Interestingly, there was a study done by 
Wiwanitkit and his workmates (2007) found that gold nanoparticles can enhance protein 
agglutination and enhance weak blood group detection. Recently, there are many 
strategies to modify the gold nanoparticle surface conjugated with ligands. For instance, 
adding polyethylene glycol (PEG) to improvise its bioreactivity for better targeting and 
cellular uptake for biomedical application (Jazayeri et al., 2016). Yet there is limited 
study to investigate the relationship between the used of gold nanoparticles and blood 









3.0 Study design 
 
This was an experimental study to elucidate the development of RBC antibody 
agglutination enhancement reaction using PEG and gold nanoparticle (PEG AuNP) for 
antibody screening. 
 
3.1 Study venue 
 
This study was mainly conducted in Advanced Medical and Dental Institute (AMDI), 
Universiti Sains Malaysia (USM) in Bertam, Penang in which: 
AMDI: 
 Animal Research Complex 
 Transfusion Medicine Unit, Advanced Diagnostic Laboratory 
 
3.2 Study duration 
 





3.3 Study variables 
 
3.3.1 Dependent variable 
 
 Agglutination scoring/ grading 
 
3.3.2 Independent variable 
 
 Type of enhancing potentiators 
 Volume/ concentration of PEG AuNP 
 
3.4 Sample size 
 
The estimated sample size in this study was calculated from objective 3 (to determine the 
optimal concentration of PEG AuNP solution for RBC antibody agglutination reaction. 
Comparable study by Wiwanitkit and his colleagues (2007) which used only two samples 
in the study. Therefore, α (two-tailed) = 0.05 (level of significance for probability to reject 
the null hypothesis which indicated Type I error rate. β= 0.80 which accept null 
hypothesis and about 20% of error is made on difference of variable under study or 
literally type II error rate.  
r = 0.999 (expected correlation coefficient) 
Standard normal deviate for α = Z α = 1.960 while standard normal deviate for β= Z β = -
0.842c = 0.5* In [(1+r)/ (1-r)] = 3.80. Thus, the total number required for the sample size 





























Figure 3.1 Flowchart of the study 
  




 PEG AuNP 




Development of PEG AuNP 
 
Data analysis 
Report writing  
Characterisation of PEG AuNP 
 UV-VIS spectrophotometry 
 
Different concentration of PEG AuNP 
 25 uL 
 50 uL 
 100 uL 
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3.6 Chemicals, Materials, and Apparatus  
 
Before synthesis, glassware was washed, rinsed with distilled water and put into the dryer 
or oven overnight at 80 to 100°C. For solvent preparation, deionised water (dH2O), and 
1% of sodium chloride solution were prepared. Polyethylene glycol (PEG) with the 
molecular weight of 4600, Chloroauric acid trihydrate (HAuCl4. 3H2O) or gold (lll) 
chloride hydrate, were purchased from Sigma Aldrich (USA) company. All the chemicals 
and equipment used throughout the experiment were tabulated in Table 3.1 and Table 3.2 
respectively as below: 
 
Table 3.1 Type of chemical used with respect to its company and country of origin 
respectively. 
Chemical Company Country of Origin 
Polyethylene glycol (PEG) Sigma Aldrich USA 
Chloroauric acid trihydrate 
(HAuCl4. 3H2O) 
Sigma Aldrich USA 
Panoscreen I and II Bio-Rad USA 
Gamma H-Hance (LISS) Immucor USA 
Diaclon Coombs Serum 
(AHG) 
Bio-Rad USA 





Table 3.2 Equipment used with respect to its manufacturer, model, and country of origin 
respectively. 
Equipment Manufacturer Model Country of Origin 
Hotplate LMS Harmony HTS-1003 Japan 
pH meter Eutech pH 700 Singapore 
Hotplate with 
temperature and speed 
monitors 
Fisher Scientific Isotemp USA 
Sonicator/ Sonic bath Jeiotech UC-10 Korea 





Rotofix 32 A Germany 
Incubator DiaMed-ID 
ID-incubator 37 
S  I 
Switzerland 




3.7 Enhancing potentiators preparation 
 
3.7.1 Preparation of PEG solution 
 
PEG stock solution was prepared based on monthly basis and the method of preparation 
was used based on Nance and Garratty (1997) and Stiufiuc and his colleagues (2013). 
Firstly, 1.24g of PEG was dissolved in deionised water and added to the final volume of 
10mL of deionised water in a 50mL beaker. The mixture was then transferred to 25mL 
of bottle and heated up on the hotplate (LMS Harmony, HTS-1003, Japan) to ensure it 
was homogeneously dissolved (Figure 3.2). Then, the mixture was cooled at room 
temperature and adjusted to pH 7 to 7.4 and kept in 4°C for storage. Prior for usage, the 
stock solution was equilibrate to room temperature before testing is carried out. 
 
 
Figure 3.2 PEG preparation. 
